# Clinical Telavancin Failure in Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia

## TL;DR

This paper reports a case where telavancin, an antibiotic, failed to treat persistent MRSA bacteremia in a patient.

## Contribution

The paper presents a clinical case of telavancin failure and investigates the underlying cause.

## Key findings

- Telavancin failed to treat persistent MRSA bacteremia in a patient.
- The cause of telavancin failure was investigated and described.

## Abstract

Telavancin is a fairly novel antibiotic derived from vancomycin developed to combat the constant evolutionary war against bacteria. It has achieved high clinical success in its role in treating Gram-positive organisms, although like in the case of any other antibiotics, failure can arise. The purpose of this article is to describe a case in which telavancin clinically failed in treating persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in a patient while describing the cause that led to telavancin failure.